Orange, CANCT07192471Now EnrollingIRB Ready

T-cell NHL (PTCL or CTCL) Clinical Trial in Orange, CA

Access cutting-edge t-cell nhl (ptcl or ctcl) treatment through this phase 1 clinical trial at a research site in Orange. Study-provided care at no cost to qualified participants.

Sponsored by Kyowa Kirin, Inc.

Quick Self-Assessment

See if you qualify for this Orange location

Preparing your pre-screening questions…

Expert Care in Orange

Access t-cell nhl (ptcl or ctcl) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related t-cell nhl (ptcl or ctcl) treatment provided free

Apply for This Orange Location

Check if you qualify for this t-cell nhl (ptcl or ctcl) clinical trial in Orange, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Orange

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Orange site if eligible
  4. 4Begin participation

About This T-cell NHL (PTCL or CTCL) Study in Orange

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Sponsor: Kyowa Kirin, Inc.

Who Can Participate

Inclusion Criteria

Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
Availability of tumor tissue (current or archival) is required.
Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
Body weight 40 kg to ≤ 200 kg
Life expectancy ≥3 months.
Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
Restrictions on gamete donation and freezing during and after treatment.
Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria

Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
Pregnant or breastfeeding females, or those intending pregnancy.
History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
Use of other investigational drugs within 14 days or 5 half-lives before treatment.
Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if \>6 months.
Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
Prolonged QT/QTc interval (e.g., QTcF \>480 ms).
Active second primary malignancies except specified non-exclusionary cases.
CNS involvement.
Any condition that may impair compliance or study completion as judged by the Investigator.
Known hypersensitivity to any excipients in the drug formulation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orange?

Yes, this clinical trial (NCT07192471) has an active research site in Orange, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

T-cell NHL (PTCL or CTCL) Treatment Options in Orange, CA

If you're searching for t-cell nhl (ptcl or ctcl) treatment options in Orange, CA, this clinical trial (NCT07192471) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orange research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced t-cell nhl (ptcl or ctcl) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all t-cell nhl (ptcl or ctcl) clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Orange, CA

See all lymphoma clinical trials recruiting in Orange — not just this study.

Browse Lymphoma Trials in Orange →

Browse More Trials by Condition

Lymphoma TrialsPeripheral T-Cell Lymphoma TrialsAll Conditions →

Ready to Join in Orange?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Orange, CA